Incretin hormones and the satiation signal

Jens Juul Holst

doi:10.1038/ijo.2012.208

Incretin hormones and the satiation signal

92 Citationer (Scopus)

Abstract

Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.

Originalsprog	Engelsk
Tidsskrift	International journal of obesity (2005)
Vol/bind	37
Udgave nummer	9
Sider (fra-til)	1161-8
Antal sider	8
ISSN	0307-0565
DOI	https://doi.org/10.1038/ijo.2012.208
Status	Udgivet - sep. 2013

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/ijo.2012.208

Citationsformater

@article{56a9e3bda2bb475e8e920cafa65d4a61,

title = "Incretin hormones and the satiation signal",

abstract = "Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.",

keywords = "Animals, Eating, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Humans, Hyperglycemia, Hypoglycemic Agents, Incretins, Obesity, Peptides, Receptors, Glucagon, Satiation, Signal Transduction, Venoms, Weight Loss",

author = "Holst, {Jens Juul}",

year = "2013",

month = sep,

doi = "10.1038/ijo.2012.208",

language = "English",

volume = "37",

pages = "1161--8",

journal = "International Journal of Obesity",

issn = "0307-0565",

publisher = "nature publishing group",

number = "9",

}

TY - JOUR

T1 - Incretin hormones and the satiation signal

AU - Holst, Jens Juul

PY - 2013/9

Y1 - 2013/9

N2 - Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.

AB - Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.

KW - Animals

KW - Eating

KW - Gastric Inhibitory Polypeptide

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Incretins

KW - Obesity

KW - Peptides

KW - Receptors, Glucagon

KW - Satiation

KW - Signal Transduction

KW - Venoms

KW - Weight Loss

U2 - 10.1038/ijo.2012.208

DO - 10.1038/ijo.2012.208

M3 - Journal article

C2 - 23295502

SN - 0307-0565

VL - 37

SP - 1161

EP - 1168

JO - International Journal of Obesity

JF - International Journal of Obesity

IS - 9

ER -

Incretin hormones and the satiation signal

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater